A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.